查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403480

到 2030 年癌症切片檢查市場預測：按產品、類型、應用、最終用戶和地區進行的全球分析

Cancer Biopsy Market Forecasts to 2030 - Global Analysis By, Product (Instruments, Kits and Consumables and Other Products), Type (Tissue Biopsies, Liquid Biopsies, Surgical Biopsies and Other Types), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球癌症切片檢查市場規模為 266 億美元，預計在預測期內將以 20% 的複合年成長率成長，到 2030 年達到 954 億美元。

癌症切片檢查是一種醫療程序，從可疑或異常的生長、腫塊或病變中取出小組織樣本並進行檢查，以確定癌細胞的存在、性質和特徵。癌症切片檢查為腫瘤學家和醫療保健專業人員提供準確、詳細的資訊，以便根據每個患者的癌症特徵做出準確的診斷並製定量身定做的治療計劃。這是有幫助的基本內容。

根據美國乳癌統計數據，美國大約八分之一的女性患有侵襲性乳癌。

癌症發生率上升

癌症仍然是一個全球性的健康問題，由於高齡化、生活方式改變、環境暴露和遺傳傾向等多種因素，越來越多的人被診斷出患有各種類型的癌症。隨著癌症患者數量的增加，對準確、及時的癌症診斷的需求也隨之增加。切片檢查程序透過取出組織樣本進行病理分析，在確認癌症診斷方面發揮重要作用。因此，癌症發生率上升是加速市場需求的關鍵因素。

高成本

高診斷成本是預計抑制全球癌症切片檢查市場成長的主要因素之一。癌症診斷測試​​價格高成本，給患者家庭帶來額外的經濟負擔。因此，這些測試對於沒有保險的中產階級患者群體來說是遙不可及的。此外，高昂的診斷成本限制了癌症篩檢技術的使用，因為許多私人公司不支付與癌症診斷相關的費用。

技術進步

技術進步導致了微創切片檢查技術的發展，例如細針抽吸（FNA）、核心切片檢查（CNB）和內視鏡切片檢查。與傳統的開放性手術相比，這些手術使用較小的切口和針頭來獲取組織樣本，減少患者不適，最大限度地降低併發症的風險，並提高康復速度。這些因素正在推動市場需求。

缺乏意識

在某些地區和人群中，一般民眾和醫療保健專業人員對切片檢查在癌症診斷中的重要角色認知不足。患者可能不完全理解切片檢查程序在確定腫瘤的性質和特徵方面的重要性，並且可能會猶豫或不願意接受此類必要的診斷測試。因此，缺乏認知是市場的主要抑制因素。

COVID-19 的影響

COVID-19 的出現對癌症切片檢查市場產生了重大影響。疫情階段，由於社交距離措施，醫院就診受到嚴格限制，只允許急診病患入院，對市場擴張產生了負面影響。此外，在疫情大流行之後，新技術的採用有所增加，為所研究的市場開闢了新的前景。

預計切片檢查部分在預測期內將是最大的

手術切片檢查領域估計佔據最大佔有率。外科切片檢查涉及在切口或外科手術過程中取出組織樣本。當需要大的組織標本進行進一步檢查時，通常會採用這種方法，以便病理學家分析腫瘤的​​特徵、惡性和範圍。對於癌症切片檢查，手術切片檢查經常用於位於深部或難以接近位置的腫瘤，在這些位置獲取足夠的組織標本對於準確的診斷和治療計劃非常重要。

預計設備領域在預測期內將呈現最高的複合年成長率。

預計家電領域在預測期內將出現良好的成長。設備在促進準確有效的切片檢查程序以及有助於準確的癌症診斷和治療決策方面發揮著至關重要的作用。這些儀器包括用於獲取組織樣本進行測試的各種儀器，包括傳統的切片穿刺針、切片檢查鉗以及專為微創手術設計的專用儀器。此外，超音波、MRI和CT掃描儀等先進的影像設備對於引導臨床醫生到特定部位進行切片檢查並提供有針對性和準確的採樣至關重要。

佔比最大的地區：

由於醫療保健基礎設施的快速進步以及對癌症早期檢測和治療的興趣日益濃厚，亞太地區在預測期內佔據了最大的市場佔有率。在中國、印度和日本等國家，癌症患者的盛行率不斷增加，這增加了對切片檢查作為診斷途徑關鍵組成部分的需求。此外，該地區致力於改善癌症治療和促進醫學研究，並在全球癌症切片檢查市場中發揮關鍵作用。

複合年成長率最高的地區：

由於先進的醫療基礎設施、癌症患者的高盛行率以及對技術創新的積極關注，預計北美在預測期內將出現有益的成長。在北美，廣泛採用各種切片檢查技術，包括手術切片檢查、針吸活體組織切片和液體活體組織切片，以獲得準確、全面的資訊，用於癌症診斷和治療計劃。此外，尖端影像技術、分子診斷和微創切片檢查方法的採用凸顯了該地區對提高診斷準確性和患者治療結果的承諾。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球癌症切片檢查市場：依產品

  • 裝置
  • 套件/消耗品
  • 其他產品

第6章全球癌症切片檢查市場：按類型

  • 組織切片檢查
    • 針吸切片
      • 細針抽吸
      • 空心針活體組織切片
    • 手術切片檢查
  • 液體活體組織切片
  • 手術切片檢查
  • 其他類型

第7章全球癌症切片檢查市場：依應用分類

  • 子宮頸癌
  • 大腸直腸癌
  • 攝護腺癌
  • 乳癌
  • 肺癌
  • 皮膚癌
  • 腎癌
  • 血癌
  • 卵巢癌
  • 肝癌
  • 胰臟癌
  • 其他用途

第8章全球癌症切片檢查市場：按最終用戶分類

  • 診斷實驗室
  • 醫院
  • 其他最終用戶

第9章全球癌症切片檢查市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Hologic, Inc.
  • NeoGenomics, Inc.
  • Koninklijke Philips NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Sysmex Corporation
Product Code: SMRC24705

According to Stratistics MRC, the Global Cancer Biopsy Market is accounted for $26.6 billion in 2023 and is expected to reach $95.4 billion by 2030 growing at a CAGR of 20% during the forecast period. A cancer biopsy is a medical procedure involving the removal and examination of a small tissue sample from a suspicious or abnormal growth, lump, or lesion to determine the presence, nature, and characteristics of cancer cells. Cancer biopsies are fundamental to providing accurate and detailed information for oncologists and healthcare professionals, helping them formulate precise diagnoses and develop tailored treatment plans based on the unique characteristics of each patient's cancer.

According to USA breast cancer statistics, about one in every eight women in the USA develops invasive breast cancer.

Market Dynamics:

Driver:

Rising cancer incidence

Cancer continues to be a global health concern, with increasing numbers of individuals being diagnosed with various types of cancer due to various factors such as aging populations, lifestyle changes, environmental exposures, and genetic predisposition. As the number of cancer cases increases, the demand for accurate and timely cancer diagnosis also grows. Biopsy procedures play a crucial role in confirming cancer diagnoses by obtaining tissue samples for pathological analysis. Therefore, rising cancer incidence is a significant factor accelerating market demand.

Restraint:

High cost

The high cost of diagnosis is one of the main factors anticipated to impede the growth of the global cancer biopsy market. Cancer diagnostic tests are highly costly, which puts additional financial strain on patient families. Thus, these tests are not affordable for middle-class patient population that is not covered under any insurance. Additionally, a number of private insurance companies do not pay for cancer diagnosis-related expenses, which means that the high cost of diagnosis restricts the use of cancer screening technologies.

Opportunity:

Technological advancements

Technological advancements have led to the development of minimally invasive biopsy techniques such as fine needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsy. These techniques use smaller incisions or needles to obtain tissue samples, reducing patient discomfort, minimizing the risk of complications, and enabling faster recovery compared to traditional open surgical biopsies. These factors enhance market demand.

Threat:

Lack of awareness

In certain regions or demographic segments, there is a lack of sufficient awareness among both the general population and healthcare professionals about the critical role of biopsies in cancer diagnosis. Patients may not fully comprehend the importance of biopsy procedures in determining the nature and characteristics of tumours, leading to hesitancy or reluctance to undergo these essential diagnostic tests. As a result, a lack of awareness is a significant restraint hampering the market.

COVID-19 Impact

The emergence of COVID-19 had a significant impact on the cancer biopsy market. Hospital visits were severely restricted during the early stages of the pandemic as a result of social distancing measures; only patients with emergencies were permitted, which had a negative effect on the market's expansion. Moreover, following the pandemic, there was a rise in the adoption of new technologies, which opened up new prospects for the market under study.

The surgical biopsies segment is expected to be the largest during the forecast period

The surgical biopsies segment is estimated to hold the largest share. A surgical biopsy involves the removal of a tissue sample through an incision or during a surgical procedure. This method is commonly employed when larger tissue specimens are needed for thorough examination, allowing pathologists to analyze the tumour's characteristics, grade, and extent of spread. In cancer biopsies, surgical biopsies are frequently utilized for tumours located in deep or challenging-to-access areas, where obtaining an adequate tissue sample is crucial for accurate diagnosis and treatment planning.

The instruments segment is expected to have the highest CAGR during the forecast period

The instruments segment is anticipated to have lucrative growth during the forecast period. Instruments play a pivotal role in facilitating precise and effective biopsy procedures, contributing to accurate cancer diagnoses and treatment decisions. These instruments encompass a wide range of devices used to obtain tissue samples for examination, including traditional biopsy needles, biopsy forceps, and specialized tools designed for minimally invasive procedures. Additionally, advanced imaging instruments such as ultrasound, MRI, and CT scanners are integral to guiding clinicians to the specific site for biopsy, ensuring targeted and accurate sampling.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to rapid advancements in healthcare infrastructure and a growing focus on early cancer detection and treatment. With a rising prevalence of cancer cases in countries like China, India, and Japan, there is an increasing demand for biopsy procedures as a crucial component of the diagnostic pathway. Moreover, the region's commitment to improving cancer care and fostering medical research positions it as a key contributor to the global cancer biopsy market.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to advanced healthcare infrastructure, a high prevalence of cancer cases, and a robust focus on technological innovation. In North America, various biopsy techniques, including surgical, needle, and liquid biopsies, are widely employed to obtain precise and comprehensive information for cancer diagnosis and treatment planning. Additionally, the adoption of cutting-edge imaging technologies, molecular diagnostics, and minimally invasive biopsy procedures underscores the region's commitment to enhancing diagnostic accuracy and patient outcomes.

Key players in the market:

Some of the key players in the Cancer Biopsy Market include Becton, Dickinson and Company, Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Illumina, Inc., Myriad Genetics, Inc., Hologic, Inc., Neo Genomics, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc., QIAGEN N.V. and Sysmex Corporation.

Key Developments:

In May 2023, Partnership between Thermo Fisher Scientific and BRIN to enable and enhance the country's national research and innovation infrastructure and capability.

In March 2023, Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.

In Jan 2023, Philips a global leader in health technology, and Masimo, a global medical technology company, announced an expansion of their partnership to augment patient monitoring capabilities in home telehealth applications with the Masimo W1™ advanced health tracking watch.

Products Covered:

  • Instruments
  • Kits and Consumables
  • Other Products

Types Covered:

  • Tissue Biopsies
  • Liquid Biopsies
  • Surgical Biopsies
  • Other Types

Applications Covered:

  • Cervical Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Skin Cancer
  • Kidney Cancer
  • Blood Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Other Applications

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Biopsy Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Kits and Consumables
  • 5.4 Other Products

6 Global Cancer Biopsy Market, By Type

  • 6.1 Introduction
  • 6.2 Tissue Biopsies
    • 6.2.1 Needle Biopsies
      • 6.2.1.1 Fine Needle Aspiration
      • 6.2.1.2 Core Needle Biopsy
    • 6.2.2 Surgical Biopsies
  • 6.3 Liquid Biopsies
  • 6.4 Surgical Biopsies
  • 6.5 Other Types

7 Global Cancer Biopsy Market, By Application

  • 7.1 Introduction
  • 7.2 Cervical Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Prostate Cancer
  • 7.5 Breast Cancer
  • 7.6 Lung Cancer
  • 7.7 Skin Cancer
  • 7.8 Kidney Cancer
  • 7.9 Blood Cancer
  • 7.10 Ovarian Cancer
  • 7.11 Liver Cancer
  • 7.12 Pancreatic Cancer
  • 7.13 Other Applications

8 Global Cancer Biopsy Market, By End User

  • 8.1 Introduction
  • 8.2 Diagnostic Laboratories
  • 8.3 Hospitals
  • 8.4 Other End Users

9 Global Cancer Biopsy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Becton, Dickinson and Company
  • 11.2 Abbott Laboratories
  • 11.3 Danaher Corporation
  • 11.4 F. Hoffmann-La Roche Ltd.
  • 11.5 Bio-Rad Laboratories, Inc.
  • 11.6 Illumina, Inc.
  • 11.7 Myriad Genetics, Inc.
  • 11.8 Hologic, Inc.
  • 11.9 NeoGenomics, Inc.
  • 11.10 Koninklijke Philips N.V.
  • 11.11 Siemens Healthineers AG
  • 11.12 Thermo Fisher Scientific Inc.
  • 11.13 QIAGEN N.V.
  • 11.14 Sysmex Corporation

List of Tables

  • Table 1 Global Cancer Biopsy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Biopsy Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Cancer Biopsy Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 4 Global Cancer Biopsy Market Outlook, By Kits and Consumables (2021-2030) ($MN)
  • Table 5 Global Cancer Biopsy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 6 Global Cancer Biopsy Market Outlook, By Type (2021-2030) ($MN)
  • Table 7 Global Cancer Biopsy Market Outlook, By Tissue Biopsies (2021-2030) ($MN)
  • Table 8 Global Cancer Biopsy Market Outlook, By Needle Biopsies (2021-2030) ($MN)
  • Table 9 Global Cancer Biopsy Market Outlook, By Surgical Biopsies (2021-2030) ($MN)
  • Table 10 Global Cancer Biopsy Market Outlook, By Liquid Biopsies (2021-2030) ($MN)
  • Table 11 Global Cancer Biopsy Market Outlook, By Surgical Biopsies (2021-2030) ($MN)
  • Table 12 Global Cancer Biopsy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 13 Global Cancer Biopsy Market Outlook, By Application (2021-2030) ($MN)
  • Table 14 Global Cancer Biopsy Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 15 Global Cancer Biopsy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 16 Global Cancer Biopsy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 17 Global Cancer Biopsy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 18 Global Cancer Biopsy Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 19 Global Cancer Biopsy Market Outlook, By Skin Cancer (2021-2030) ($MN)
  • Table 20 Global Cancer Biopsy Market Outlook, By Kidney Cancer (2021-2030) ($MN)
  • Table 21 Global Cancer Biopsy Market Outlook, By Blood Cancer (2021-2030) ($MN)
  • Table 22 Global Cancer Biopsy Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 23 Global Cancer Biopsy Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 24 Global Cancer Biopsy Market Outlook, By Pancreatic Cancer (2021-2030) ($MN)
  • Table 25 Global Cancer Biopsy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 26 Global Cancer Biopsy Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Cancer Biopsy Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 28 Global Cancer Biopsy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Cancer Biopsy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.